Dr Harry Weisinger MD, Ph.D.

Doctor with a special interest in the science, art and medicine of longevity and performance.

[Dr Harry Weisinger MD, Ph.D. @myperformancedr]

@maciejbanach @pabeda1 @rauldsf_santos Exciting!! Where can I see this data?

[Thomas Dayspring @Drlipid]

From authors at the NIH: ApoB is superior to non-HDL-C & is cost-effective. In the current paradigm of precision medicine, the value of the additional precision of apoB will ultimately result in its adoption as the primary risk marker for ASCVD. @society_EAS @nationallipid https://t.co/dR53yHKa2W

[Dr Harry Weisinger MD, Ph.D. @myperformancedr]

Think you can keep up?

#Science #scientometrics #keepup

[Dr Harry Weisinger MD, Ph.D. @myperformancedr]

I shouldn't have surprised, but I was!

I asked Google's Bard GPT whether there are studies demonstrating a benefit in the post-operative use of recombinant hGH.

Quickly and conveniently, Bard provided a list of studies, authors, even DOIs. What a time-saver!

Unfortunately...